Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Sunlenca
Lenacapavir is a first-in-class, long-acting HIV-1 capsid inhibitor indicated, in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection. It works by targeting the HIV-1 capsid, a protein shell that protects the virus's genetic material. By inhibiting the capsid, lenacapavir disrupts multiple stages of the viral life cycle, including viral replication, assembly, and integration into the host cell's DNA.
Lenacapavir is used in combination with other antiretrovirals to treat multi-drug resistant HIV-1 infection in heavily treatment-experienced adults.
Outcome:
Decreased lenacapavir levels
Mechanism:
CYP3A4 induction
Outcome:
Increased lenacapavir levels
Mechanism:
CYP3A4 inhibition
Outcome:
Decreased lenacapavir absorption
Mechanism:
Chelation
Most likely new formulation: Long-acting implantable formulation (Year 2025, 75% confidence)
Based on current clinical trial data and uptake trends, there is a 90% likelihood of lenacapavir maintaining its approved status for multi-drug resistant HIV-1.
Antiretroviral, Capsid Inhibitor
Benzimidazole derivative